KR101623357B1 - 5-ｈｔ6 길항제로서 아릴설포닐 피라졸린 카복스아미딘 유도체 - Google Patents
5-ｈｔ6 길항제로서 아릴설포닐 피라졸린 카복스아미딘 유도체 Download PDFInfo
- Publication number
- KR101623357B1 KR101623357B1 KR1020107022926A KR20107022926A KR101623357B1 KR 101623357 B1 KR101623357 B1 KR 101623357B1 KR 1020107022926 A KR1020107022926 A KR 1020107022926A KR 20107022926 A KR20107022926 A KR 20107022926A KR 101623357 B1 KR101623357 B1 KR 101623357B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- group
- compound
- thienyl
- substituted
- Prior art date
Links
- 0 CC1=C*(*)C=C2NC*(*)CC2=C1 Chemical compound CC1=C*(*)C=C2NC*(*)CC2=C1 0.000 description 5
- ZDZOGGYUYCMFIS-UHFFFAOYSA-N CC/N=C(/N)\N1N=CC(C)(C)C1 Chemical compound CC/N=C(/N)\N1N=CC(C)(C)C1 ZDZOGGYUYCMFIS-UHFFFAOYSA-N 0.000 description 1
- HRDFVQLHRAQAKQ-UHFFFAOYSA-N CC/N=C(/N)\SC Chemical compound CC/N=C(/N)\SC HRDFVQLHRAQAKQ-UHFFFAOYSA-N 0.000 description 1
- WJIPRLMEAZGAJT-UHFFFAOYSA-N CC1(C)CN=NC1 Chemical compound CC1(C)CN=NC1 WJIPRLMEAZGAJT-UHFFFAOYSA-N 0.000 description 1
- AGFXSACKPRQRNH-UHFFFAOYSA-N CCC(C1)C=NN1/C(/NCC)=N/S(c(cc1)ccc1N)(=O)=O Chemical compound CCC(C1)C=NN1/C(/NCC)=N/S(c(cc1)ccc1N)(=O)=O AGFXSACKPRQRNH-UHFFFAOYSA-N 0.000 description 1
- GORZRAQAEVJRDK-UHFFFAOYSA-N CCN/C(/N1N=CC(C)(C)C1)=N\S(c(cc1Cl)ccc1N)(=O)=O Chemical compound CCN/C(/N1N=CC(C)(C)C1)=N\S(c(cc1Cl)ccc1N)(=O)=O GORZRAQAEVJRDK-UHFFFAOYSA-N 0.000 description 1
- FSQZLTAHKDYTBU-UHFFFAOYSA-N CCN/C(/N1N=CC(C)(C)C1)=N\S(c(cc1Cl)ccc1NC(C)=O)(=O)=O Chemical compound CCN/C(/N1N=CC(C)(C)C1)=N\S(c(cc1Cl)ccc1NC(C)=O)(=O)=O FSQZLTAHKDYTBU-UHFFFAOYSA-N 0.000 description 1
- AWMAQSJTJCPAAB-UHFFFAOYSA-N CCN/C(/N1N=CC2(CCCC2)C1)=N\S(c1ccc(CO)cc1)(=O)=O Chemical compound CCN/C(/N1N=CC2(CCCC2)C1)=N\S(c1ccc(CO)cc1)(=O)=O AWMAQSJTJCPAAB-UHFFFAOYSA-N 0.000 description 1
- PKROBCVIFMCNTC-UHFFFAOYSA-N Clc1cc(OCc2ccccc2)cc(Br)c1 Chemical compound Clc1cc(OCc2ccccc2)cc(Br)c1 PKROBCVIFMCNTC-UHFFFAOYSA-N 0.000 description 1
- GYOSZNOOKZSAHO-UHFFFAOYSA-N O=S(c1cc(Cl)cc(OCc2ccccc2)c1)(Cl)=O Chemical compound O=S(c1cc(Cl)cc(OCc2ccccc2)c1)(Cl)=O GYOSZNOOKZSAHO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08152873.9 | 2008-03-18 | ||
| EP08152873 | 2008-03-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20100136504A KR20100136504A (ko) | 2010-12-28 |
| KR101623357B1 true KR101623357B1 (ko) | 2016-05-23 |
Family
ID=39639064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107022926A KR101623357B1 (ko) | 2008-03-18 | 2009-03-17 | 5-ｈｔ6 길항제로서 아릴설포닐 피라졸린 카복스아미딘 유도체 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8563723B2 (pt) |
| EP (2) | EP2610247B1 (pt) |
| JP (1) | JP5504252B2 (pt) |
| KR (1) | KR101623357B1 (pt) |
| CN (2) | CN102036967B (pt) |
| AR (1) | AR070898A1 (pt) |
| AU (1) | AU2009226956C1 (pt) |
| BR (1) | BRPI0908738A8 (pt) |
| CA (1) | CA2717922A1 (pt) |
| CO (1) | CO6290679A2 (pt) |
| CR (1) | CR11742A (pt) |
| DK (2) | DK2610247T3 (pt) |
| DO (2) | DOP2010000276A (pt) |
| EA (1) | EA023176B1 (pt) |
| EC (1) | ECSP10010476A (pt) |
| ES (2) | ES2565184T3 (pt) |
| HK (2) | HK1152708A1 (pt) |
| IL (1) | IL207846A0 (pt) |
| MX (1) | MX2010010299A (pt) |
| MY (1) | MY155318A (pt) |
| NZ (1) | NZ587743A (pt) |
| PH (1) | PH12013502376B1 (pt) |
| PL (2) | PL2610247T3 (pt) |
| PT (1) | PT2610247T (pt) |
| SG (1) | SG183688A1 (pt) |
| TW (1) | TWI557110B (pt) |
| UA (1) | UA105629C2 (pt) |
| WO (1) | WO2009115515A1 (pt) |
| ZA (1) | ZA201006272B (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR079935A1 (es) | 2010-01-29 | 2012-02-29 | Abbott Healthcare Products Bv | Sintesis de derivados de pirazolin carboxamidina sustituida |
| MX356486B (es) * | 2011-08-15 | 2018-05-30 | Univ Utah Res Found | Análogos sustituidos de la (e)-n' -(1-feniletiliden)benzohidrazida como inhibidores de la histona desmetilasa. |
| SG11201503562PA (en) | 2012-11-16 | 2015-06-29 | Bristol Myers Squibb Co | Dihydropyrazole gpr40 modulators |
| DK2920165T3 (en) * | 2012-11-16 | 2017-01-16 | Bristol Myers Squibb Co | Dihydropyrazol-GPR40-MODULATORS |
| CN104918935B (zh) * | 2012-11-16 | 2017-07-28 | 百时美施贵宝公司 | 二氢吡唑gpr40调节剂 |
| CN106660968B (zh) * | 2014-05-09 | 2020-02-07 | 美国政府(由卫生和人类服务部的部长所代表) | 吡唑衍生物及其作为大麻素受体介体的用途 |
| US10385040B2 (en) | 2014-08-12 | 2019-08-20 | Loyola University Of Chicago | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same |
| EP3109237A1 (en) * | 2015-06-22 | 2016-12-28 | AnaMar AB | Novel 5-ht2 antagonists |
| CN107460160A (zh) * | 2017-08-23 | 2017-12-12 | 世贸天阶制药（江苏）有限责任公司 | 一种cho细胞无血清培养基 |
| US10879709B2 (en) | 2018-05-31 | 2020-12-29 | National Taipei University Of Technology | Power management system and operating method thereof |
| MX2022004367A (es) | 2019-10-09 | 2022-05-06 | Bayer Ag | Nuevos compuestos de heteroarilo-triazol como pesticidas. |
| CA3185968A1 (en) | 2020-07-13 | 2022-01-20 | Tony Lahoutte | Antibody fragment against folr1 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003026648A1 (en) | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0422263D0 (en) * | 2004-10-07 | 2004-11-10 | Glaxo Group Ltd | Novel compounds |
| AR062907A1 (es) * | 2006-09-22 | 2008-12-17 | Solvay Pharm Bv | Derivados de sulfonilpirazol y sulfonilpirazolincarboxamidina como antagonistas de 5-ht6 |
-
2009
- 2009-03-13 AR ARP090100917A patent/AR070898A1/es unknown
- 2009-03-16 TW TW098108412A patent/TWI557110B/zh not_active IP Right Cessation
- 2009-03-17 CA CA2717922A patent/CA2717922A1/en not_active Abandoned
- 2009-03-17 KR KR1020107022926A patent/KR101623357B1/ko not_active IP Right Cessation
- 2009-03-17 DK DK13161112.1T patent/DK2610247T3/en active
- 2009-03-17 JP JP2011500192A patent/JP5504252B2/ja not_active Expired - Fee Related
- 2009-03-17 MX MX2010010299A patent/MX2010010299A/es active IP Right Grant
- 2009-03-17 UA UAA201012295A patent/UA105629C2/uk unknown
- 2009-03-17 EP EP13161112.1A patent/EP2610247B1/en not_active Not-in-force
- 2009-03-17 US US12/933,182 patent/US8563723B2/en active Active
- 2009-03-17 MY MYPI2010004094A patent/MY155318A/en unknown
- 2009-03-17 NZ NZ587743A patent/NZ587743A/en not_active IP Right Cessation
- 2009-03-17 PT PT131611121T patent/PT2610247T/pt unknown
- 2009-03-17 CN CN200980108113.0A patent/CN102036967B/zh not_active Expired - Fee Related
- 2009-03-17 DK DK09721279.9T patent/DK2265589T3/en active
- 2009-03-17 AU AU2009226956A patent/AU2009226956C1/en not_active Ceased
- 2009-03-17 CN CN201410233817.3A patent/CN104003937A/zh active Pending
- 2009-03-17 EP EP09721279.9A patent/EP2265589B1/en active Active
- 2009-03-17 WO PCT/EP2009/053133 patent/WO2009115515A1/en active Application Filing
- 2009-03-17 SG SG2012057592A patent/SG183688A1/en unknown
- 2009-03-17 EA EA201071083A patent/EA023176B1/ru not_active IP Right Cessation
- 2009-03-17 PL PL13161112T patent/PL2610247T3/pl unknown
- 2009-03-17 BR BRPI0908738A patent/BRPI0908738A8/pt not_active IP Right Cessation
- 2009-03-17 ES ES09721279.9T patent/ES2565184T3/es active Active
- 2009-03-17 ES ES13161112.1T patent/ES2577867T3/es active Active
- 2009-03-17 PL PL09721279T patent/PL2265589T3/pl unknown
-
2010
- 2010-08-29 IL IL207846A patent/IL207846A0/en unknown
- 2010-09-01 ZA ZA2010/06272A patent/ZA201006272B/en unknown
- 2010-09-13 DO DO2010000276A patent/DOP2010000276A/es unknown
- 2010-09-13 EC EC2010010476A patent/ECSP10010476A/es unknown
- 2010-09-14 CO CO10113567A patent/CO6290679A2/es active IP Right Grant
- 2010-09-14 DO DO2010000277A patent/DOP2010000277A/es unknown
- 2010-10-15 CR CR11742A patent/CR11742A/es unknown
-
2011
- 2011-07-05 HK HK11106876.3A patent/HK1152708A1/xx not_active IP Right Cessation
- 2011-07-05 HK HK15101929.7A patent/HK1201823A1/xx unknown
-
2013
- 2013-09-11 US US14/024,030 patent/US8901108B2/en not_active Expired - Fee Related
- 2013-11-18 PH PH12013502376A patent/PH12013502376B1/en unknown
-
2014
- 2014-10-29 US US14/527,651 patent/US9126942B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003026648A1 (en) | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101623357B1 (ko) | 5-ｈｔ6 길항제로서 아릴설포닐 피라졸린 카복스아미딘 유도체 | |
| EP2069310B1 (en) | Sulfonylpyrazoline-1-carboxamidine derivatives as 5-ht6 antagonists | |
| EP2964223B1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| JP2019529490A (ja) | 嚢胞性線維症膜コンダクタンス制御因子の調節因子、医薬組成物、処置の方法、及び当該調節因子を作製するためのプロセス | |
| JP2016537369A (ja) | カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体 | |
| KR20110051226A (ko) | Ｃｒｆ1 길항제로서의 피라졸로[5,1-ｂ]옥사졸 유도체 | |
| KR20100031578A (ko) | 5-ｈｔ6 수용체 친화성을 갖는 4'-치환된 화합물 | |
| EP2986616B1 (en) | Tricyclic triazolic compounds as sigma receptors ligans | |
| CA3219801A1 (en) | Substituted heterobicyclic derivatives as negative allosteric modulators of mglu7 receptor | |
| JP2018531267A (ja) | 疼痛に対して活性を有するオキサ−アザスピロ化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| N231 | Notification of change of applicant | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |